About
PI3K/mTOR therapies, Companion Diagnostics
Areas of Focus
Categories
DiagnosticsSmall Molecule PharmaceuticalMidwest
Team (32)
Clinical Trials (11)
View allTotal Trials
11
As Lead Sponsor
5
As Collaborator
6
Total Enrollment
1,888
By Phase
PHASE3: 2PHASE1/PHASE2: 3PHASE2: 4PHASE1: 1
By Status
RECRUITING: 4ACTIVE_NOT_RECRUITING: 2WITHDRAWN: 1TERMINATED: 1UNKNOWN: 1COMPLETED: 1AVAILABLE: 1
Clinical Trials Pipeline10 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
Today
Hover over trial bars to see details
Recent Trials
NCT06757634Lead Sponsor
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
PHASE3Recruiting
674 participants
Started: Jun 30, 2025 · Completed: Dec 30, 2028
NCT06190899Lead Sponsor
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
PHASE1/PHASE2Recruiting
54 participants
Started: Jan 1, 2024 · Completed: Nov 30, 2027
NCT04901299Collaborator
Fulvestrant + Neratinib In Breast Cancer
PHASE2Withdrawn
Started: Jul 31, 2023 · Completed: Jul 1, 2025
NCT05501886Lead Sponsor
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
PHASE3Recruiting
701 participants
Started: Dec 8, 2022 · Completed: Dec 31, 2026
NCT05243641Collaborator
Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test
PHASE1/PHASE2Terminated
10 participants
Started: Aug 18, 2022 · Completed: Nov 19, 2024
Locations (1)
Headquarters
Minneapolis, MN, United States
Map
Loading map...